Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Sanofi","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Begins Dosing of DNL758 in Phase Ib Covid-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals for DNL758

    Menu

    DNL758

    DEVELOPMENTS

    PRICE INFORMATION

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sanofi

              Contact Supplier
              • Development Update
              Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
              Contact Supplier Contact Supplier
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sanofi Begins Dosing of DNL758 in Phase Ib Covid-19 Trial

              Details:

              Dosing of DNL758 has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19.

              Lead Product(s): DNL758

              Therapeutic Area: Infections and Infectious Diseases Product Name: SAR443122

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Denali Therapeutics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 30, 2020

              Sanofi Company Banner

              WBC 2024

              Not Confirmed

              envelop Contact Supplier

              Denali Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients

              Details:

              Dosing of DNL758 (SAR443122) has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19.

              Lead Product(s): DNL758

              Therapeutic Area: Infections and Infectious Diseases Product Name: SAR443122

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Bora Pharmaceuticals- Making success more certain.
              AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
              Post Enquiry
              POST ENQUIRY